Area of research
Genetics · Neurology
Research interest
Maryam Fouladi, MD, MSc, FRCP, is a pediatric neuro-oncologist, co-executive director of the pediatric neuro-oncology program at Nationwide Children’s Hospital, and a Professor of Pediatrics at the Ohio State University College of Medicine. Dr. Fouladi is an internationally recognized expert in pediatric brain tumors, and is particularly renowned for her work in phase I clinical trials. She is the founding director of CONNECT, an international consortium focused on developing and testing novel therapies in early phase clinical trials. Fouladi’s primary research interest focus on brain stem gliomas (DIPG) and is the founding Chair of The International Diffuse Intrinsic Pontine Glioma (DIPG)/diffuse midline glioma (DMG) Registry. She has authored or co-authored over 140 peer-reviewed publications in leading medical journals. In addition to her roles at Nationwide Children’s and Ohio State Wexner Medical Center, Dr. Fouladi serves as the Chair of the Collaborative Network for Neuro-Oncology Clinical Trials and CNS Committee of the Children’s Oncology Group. Prior to coming to Nationwide Children’s, Dr. Fouladi served as medical director of the Brain Tumor Center at Cincinnati Children’s Hospital and was also a full professor and the Marjory J. Johnson Endowed Chair in Brain Tumor Translational Research. She received her medical degree from the University of Toronto, and completed her pediatric residency and hematology/oncology fellowship at The Hospital for Sick Children in Toronto. She completed her neuro-oncology fellowship training at St. Jude Children’s Research Hospital followed by additional training in the Molecular Pharmacology Department at St. Jude Children’s Hospital.
Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children’s Oncology Group
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions.
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4
Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group.
Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children's Oncology Group study.
A phase 2 PBTC study of selumetinib for recurrent/progressive pediatric low-grade glioma: Strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4.
IMMU-79. An Updated Analysis of PD1 and Immune Pathway Activity in Malignant Pediatric Central Nervous System (CNS) Tumors: A Pediatric Brain Tumor Consortium (PBTC) Study, PBTC-N13
Central nervous system tumors in adolescents and young adults: A Society for Neuro-Oncology Consensus Review on diagnosis, management, and future directions
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors
Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201
Vorinostat, temozolomide or bevacizumab with irradiation and maintenance BEV/TMZ in pediatric high-grade glioma: A Children's Oncology Group Study.
Preclinical pediatric brain tumor models for immunotherapy: Hurdles and a way forward.
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group.
LGG-05. REPORT ON PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC)-029B, A PROSPECTIVE PHASE 2 CLINICAL TRIAL OF SELUMETINIB IN TREATING YOUNG PATIENTS WITH RECURRENT/PROGRESSIVE LOW-GRADE GLIOMA: NEW RESULTS ON STRATA 2, 5, AND 6 WITH UPDATED LONG-TERM SURVIVAL OUTCOMES ON STRATA 1, 3, AND 4
The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer
Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).
Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group
Evaluating preclinical evidence for clinical translation in childhood brain tumours: Guidelines from the CONNECT, PNOC, and ITCC brain networks
Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children's Oncology Group report.
Phase II trial of response-based radiation therapy for patients with localized germinoma: a Children's Oncology Group study.
Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026).
Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data
Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.
Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group.
A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors
Volumetric endpoints in diffuse intrinsic pontine glioma: comparison to cross-sectional measures and outcome correlations in the International DIPG/DMG Registry.
Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study
Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data.
Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry.
Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: A CONNECT pediatric neuro-oncology consortium report.